Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review

Published:2023-07 Issue:4 Volume:1878 Page:188927
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Wang Chao,Zhang Yujing,Chen Wujun,Wang Yanhong,Xing Dongming

Funder

Medical and Health Science and Technology Development Project of Shandong Province

Natural Science Foundation of Shandong Province

Qingdao University

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference74 articles.

1. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat. Rev. Cancer,2007

2. Targeting EGFRT790M mutation in NSCLC: from biology to evaluation and treatment;Passaro;Pharmacol. Res.,2017

3. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization;Shan;Cell,2012

4. Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy;Tan;J. Med. Chem.,2022

5. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy;Ayati;Bioorg. Chem.,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the potential mechanism of ginsenoside Rg1 to regulate ferroptosis in Alzheimer's disease based on network pharmacology;European Journal of Pharmacology;2024-09

2. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

3. A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia;2024-08-21

4. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08

5. A breast cancer targeted photodynamic degrader to activate immunotherapy through EGFR degradation mediated PD-L1 downregulation;Chemical Engineering Journal;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3